A new vaccine to prevent triple-negative breast cancer
TO TITLE: A NOVEL MRNA VACCINE TO PREVENT TRIPLE NEGATIVE BREAST CANCERIDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS
['FUNDING_OTHER'] · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · NIH-11122378
This study is testing a new mRNA vaccine designed to help prevent triple-negative breast cancer, which is a tough type of breast cancer, by boosting the immune system to fight it early on, and it's aimed at people who are at risk of developing this cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR (nih funded) |
| Locations | 1 site (OKLAHOMA CITY, UNITED STATES) |
| Trial ID | NIH-11122378 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel mRNA vaccine aimed at preventing triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer. The approach involves targeting specific proteins that are overexpressed in TNBC, using a multivalent vaccine that combines multiple antigens to elicit a stronger immune response. The vaccine will be tested in animal models to evaluate its effectiveness in preventing the onset of TNBC. By targeting the disease early, the research aims to improve outcomes for patients at risk of developing this cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for developing triple-negative breast cancer, particularly those with a family history or genetic predisposition.
Not a fit: Patients who already have a diagnosis of triple-negative breast cancer or those with other types of breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a preventive vaccine that significantly reduces the incidence of triple-negative breast cancer.
How similar studies have performed: Other research has shown promise in developing vaccines targeting specific antigens in various cancers, suggesting that this approach could be effective for TNBC as well.
Where this research is happening
OKLAHOMA CITY, UNITED STATES
- UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR — OKLAHOMA CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RAO, CHINTHALAPALLY V. — UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
- Study coordinator: RAO, CHINTHALAPALLY V.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancers